ALAnna Vladimirovna Lebedeva

Anna Vladimirovna Lebedeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Vladimirovna Lebedeva has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nutritional deficiency in patients with newly diagnosed diffuse large B-cell lymphoma Prevalence and approaches to correction

    by O. A. Obukhova, I. A. Kurmukov, A. A. Semenova, A. V. Lebedeva, A. S. Ivanova, N. Yu. Shagina

    Background. Assessing nutritional status at the start of treatment for patients with diffuse large B-cell lymphoma allows us to plan adequate accompanying treatment for patients in whom early nutritional support can improve the results of antitumor treatment.Aim. To assess the prevalence of nutritional deficiency, features of usual diet energy and protein composition in patients with diffuse large B-cell lymphoma who are starting antitumor treatment.Materials and methods. The study included 96 adult patients (m = 61), average age 38.9 ± 16.8 years, with newly diagnosed diffuse large B-cell lymphoma of various localization and prevalence. Additional laboratory screening (total protein, albumin, C-reactive protein (CRP), total cholesterol, triglycerides, daily urea excretion), anthropometric measurements (height, body weight (BW), weight loss over 6 months, body mass index), questionnaire (considering the intake of nutrients during the previous 3 days, calculating the intake of protein and energy, nitrogen balance) were performed in all patients before the first course of antitumor treatment. GLIM (Global Leadership Initiative on Malnutrition) criteria were used to diagnose protein-energy malnutrition (PEM).Results. In studied patients, energy intake was 27.92 ± 6.47 kcal/kg BW per day, protein 0.91 ± 0.18 g/kg BW per day, and nitrogen balance was –3.57 ± 2.94 g/day. Moderate PEM was diagnosed in 37 (38.5 %) patients. Differences in some laboratory parameters were revealed in patients with PEM and without nutritional disorders: CRP level (20.38 ± 14.69 mg/L versus 12.52 ± 5.66 mg/L; p = 0.0004), glucose (5.07 ± 1.09 mmol/L versus 4.57 ± 0.62 mmol/L; p = 0.005), total cholesterol (4.35 ± 1.27 mmol/L versus 5.36 ± 1.45 mmol/L), triglycerides (1.22 ± 0.51 mmol/L versus 2.02 ± 0.78 mmol/L; p = 0.001).Conclusion. Moderate PEM is detected in more than a third of patients with diffuse large B-cell lymphoma who begin antitumor treatment. The leading symptom in this case is unintentional weight loss over the past 6 months. An increased CRP level, moderate hyperglycemia, and lower concentrations of total cholesterol and blood triglycerides also characterize PEM in this cohort of patients. With sufficient energy supply, the amount of protein in the natural diet of patients with PEM turned out to be low, and the nitrogen balance was negative, which in the future can lead to the development of sarcopenia and requires nutritional support.


  • Open Access

    Biochemical factors in the blood serum of neuroendocrine tumor patients with carcinoid syndrome

    by N. V. Lyubimova, Yu. S. Timofeev, A. V. Lebedeva, A. V. Artamonova, I. S. Stilidi, N. E. Kushlinskii

    Introduction. Carcinoid syndrome is the most common functional syndrome in patients with neuroendocrine tumors. More than 40 biochemical factors are responsible for the manifestation of carcinoid syndrome, among which serotonin is the most important. The study of biochemical markers of carcinoid syndrome and associated carcinoid heart disease is an important aim of laboratory examination in neuroendocrine tumors patients.Aim. Analysis of levels and diagnostic efficiency evaluation of chromogranin A (CgA), serotonin, pro-brain natriuretic peptide (proBNP) and platelet-derived growth factor (PDGF-BB) in the blood serum of neuroendocrine tumors patients with various clinical manifestations, including carcinoid syndrome and carcinoid heart disease.Materials and methods. 66 patients with neuroendocrine tumors of various localizations were examined (pancreas – 24 cases, small intestine – 21, large intestine – 6, lungs – 10, unkown primary focus – 5). 38 patients had liver metastases. In 43 patients, a clinic of carcinoid syndrome was observed, 16 had signs of carcinoid heart disease. The control group consisted of 30 practically healthy people. Serum levels of CgA, serotonin, and PDGF-BB were determined by enzyme immunoassay in microplate format: Chromogranin A NEOLISA (Eurodiagnostica, Sweden), Serotonin ELISA (IBL, German), and PDGF-BB ELISA Kit (Invitrogen, USA). The proBNP analysis was performed on a Cobas e601 automated analyzer (Roche, Switzerland).Results. In carcinoid syndrome, the medians of CgA, serotonin, and proBNP were the highest, differing statistically significantly from the control group. In patients with G3 tumors, the median PDGF-BB was statistically significantly higher than in controls, in contrast to G1 and G2. The highest diagnostic sensitivity in the general neuroendocrine tumors group was in CgA – 63.6 %, with a specificity of 100 %. In patients with carcinoid syndrome, the highest diagnostic sensitivity was characteristic of serotonin and chromogranin A (79 %), while in patients with CAD clinic, proBNP had the highest sensitivity – 93.8 %.Conclusion. The study revealed the high efficiency of СgA, with the highest sensitivity in common forms and tumors with high biological activity. Serotonin can be used in the diagnosis of carcinoid syndrome, associated with cardiofibrosis development. Pro-brain natriuretic peptide is a highly sensitive and specific marker of carcinoid heart disease. The highest levels of PDGF-BB are associated with a high grade of neuroendocrine tumors malignancy.

  • Progastrin-releasing peptide (proGRP) and neuron specific enolase (NSE) in survival prognosis in patients with small cell lung cancer

    by Nina Vasilievna Lyubimova, Alexander Evgenievich Kuzminov, Anna Vladimirovna Lebedeva, Yury Sergeevich Timofeev, Marina Gennadievna Toms, Ivan Sokratovich Stilidi, Nikolai Evgenievich Kushlinskii

    Введение. Мелкоклеточный рак легкого (МРЛ) относится к высокоагрессивным типам опухолей, в качестве потенциальных биохимических маркеров прогноза которого рассматриваются различные соединения, включая нейронспецифическую енолазу (НСЕ), хромогранин А (ХгА), програстрин релизинг пептид (proGRP). Цель исследования. Анализ связи базальных сывороточных концентраций биохимических маркеров proGRP, НСЕ и ХгА с прогнозом выживаемости без прогрессирования (ВБП) у больных МРЛ. Методы. Обследованы 62 больных МРЛ поздних стадий (III-IV), получавших лечение с применением современных протоколов. ВБП оценивали от начала 1-го курса химиотерапии (ХТ) до времени выявления прогрессирования. Определение proGRP и НСЕ в сыворотке крови выполняли на автоматическом биохимическом анализаторе Cobas e601 (Roche). Анализ ХгА проводили методом ИФА (Eurodiagnostica). Результаты. Медианы всех исследуемых маркеров у больных МРЛ статистически значимо отличались от контроля. Выявлена зависимость между базальными уровнями proGRP в сыворотке крови и ВБП у больных МРЛ (p=0,0039), при этом в группе пациентов с уровнями proGRP более 1384 пг/мл прогноз был менее благоприятным. Анализ выживаемости с учетом уровней НСЕ показал, что в группе больных МРЛ с уровнями маркера более 72,9 нг/мл прогноз выживаемости был менее благоприятным (p=0,015). Одновременное повышение секреции proGRP и НСЕ является прогностически неблагоприятным фактором. Заключение. ProGRP и НСЕ могут быть использованы в качестве факторов прогнозирования ВБП у пациентов с распространенными стадиям МРЛ, при этом высокие уровни маркеров ассоциированы с менее благоприятным...

  • Open Access

    Сравнительное исследование хромогранина А и хромогранина В у больных с нейроэндокринными опухолями желудка и поджелудочной железы

    by N. V. Lyubimova, Yu. S. Timofeev, A. V. Lebedeva, N. E. Kushlinskii

    Introduction. Immunoenzyme assay of biochemical markers is one of the most important methods for examination of pa- tients with neuroendocrine tumors (NETs). Along with the generally accepted NET marker chromogranin A (CgA), another member of the granin family, chromogranin B (CgB), can serve as a complementary marker.Objectives. Analysis of CgB as an additional to CgA biochemical marker in the blood serum of patients with gastric and pancreatic neuroendocrine tumors.Materials and methods. We examined 79 patients with gastic (n = 14) and pancretic (n = 65) NETS, and 42 particularly healthy people, who were included in the control group. CgB and CgA were determined with ELISA method using the Human Chromogranin B (USCN, China) and Chromogranin A NEOLISA (Eurodiagnostica, Sweden) test systems., Results. CgB levels in gastric and pancreatic NETs were significantly higher than in control group. CgB concentrations were independent of tumor spread and its biological activity. ROC analysis in common group of NETs relative to control group showed AUC for CgB = 0.869 and for CgA AUC = 0.82. According to results in common group of NET patients when used isolated, CgA and CgB have comparable diagnostic sensitivity, which increases in complex use to 82.5 %. In the group of NET patients with low levels of CgA (100 ng/ml), an increase in CgB concentration above the cut-off level (15.7 ng/ml) was observed in 53.6 % of cases.Conclusion. The combination of CgB and CgA in gastric and pancreatic NETs could increase the diagnostic efficacy of bio- chemical diagnostics. The received data confirms the significance of CgB as a complementary biomarker of NETs.

  • Open Access

    EVALUATION OF PROGNOSTIC VALUE OF INFLAMMATORY MARKERS IN CHILDREN WITH CANCERS

    by E. G. Golovnya, Array В. Сотников, V. N. Baykova, Array В. Лебедева, Array Н. Байкова

    ОЦЕНКА ПРОГНОСТИЧЕСКОЙ ЗНАЧИМОСТИ МАРКЕРОВ ВОСПАЛЕНИЯ У ДЕТЕЙ С ОНКОПАТОЛОГИЕЙ